PrimeCell(TM) Therapeutics Invited to Present Its Germ Line Research at Vatican's International Stem Cell Conference
Posted on: Wednesday, 13 September 2006, 09:01 CDT
PrimeCell(TM) Therapeutics LLC (http://www.primecelltherapeutics.com) today announced that its lead stem cell researcher, Francisco Silva, has been invited to present the company's germ cell reprogramming technology at an international conference on stem cell research organized by the Pontifical Academy for Life and the World Federation of Catholic Medical Associations.
The conference participants will be given a private meeting with Pope Benedict XVI.
The conference, "Stem Cells: What Future For Therapy?", is being held Sept. 14-16 at the Augustinianum Institute, near Vatican City. It covers scientific updates addressing medical advances in the field and the prospects for clinical applications of stem cell research. The conference also offers a forum for discussing the ethical issues associated with such research. Participants include healthcare administrators, doctors, medical researchers and lawmakers from the United States, Germany, England, Australia, Italy and Portugal.
"It's a tremendous honor to be invited to personally present our research to the Pontifical Academy for Life and the World Federation of Catholic Medical Associations," said Thomas C.K. Yuen, PrimeCell Therapeutics chairman and CEO. "It is the hallmark of great leadership to gather experts, carefully consider the facts and discuss solutions. This is an excellent forum for addressing issues that impact everyone on some level, and we're extremely gratified to be included among such prestigious colleagues from around the world."
About PrimeCell(TM) Therapeutics LLC
PrimeCell(TM) Therapeutics LLC, a PrimeGen Biotech company, is devoted exclusively to adult stem cell reprogramming. Its next generation stem cell -- PrimeCell(TM) -- is an adult stem cell derived from the germ line and reprogrammed to exhibit pluripotency. Its innovative science and unique approach qualify PrimeCell Therapeutics as one of the preeminent biotechnology firms within the emerging field of regenerative medicine.
Source: Business Wire
Related Articles
- International Stem Cell Corporation Signs Agreement With BioTime, Inc., And Embryome Sciences, Inc., To Provide Unique Human Stem Cell Lines for Research Use
- International Stem Cell Corporation Signs Letter of Intent With BioTime, Inc., And Embryome Sciences to Provide Unique Human Stem Cell Lines for Research Use
- GlaxoSmithKline and OncoMed Pharmaceuticals Form Strategic Alliance to Develop Cancer Stem Cell Antibody Therapeutics
- Journal of Neuroimmunology Publishes Study Results Showing That Geron's Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack By the Human Immune System
- CellCyte Executives Highlight Plans for Breakthrough Stem Cell-Enabling Therapeutic Products, Devices Providing Innovative Solutions in Organ Repair
- Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Geron's Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
- Research Indicates Geron's Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack By the Human Immune System
- Texas Institute for Genomic Medicine Now Selling Mouse Embryonic Stem Cell Clones for Research
- NeoStem Highlights Business Model to Capitalize on Projected $8.5 Billion Market for Stem Cell-Based Therapeutics in New Investor Fact Sheet
- Geron Announces Publication of Study Results Supporting Safety and Utility of Human Embryonic Stem Cell-Derived Therapeutic Product for Treatment of Spinal Cord Injury
 |
 |
User Comments (0)
RSS Feeds